It has been 11 years since Japanese-owned Terumo Corp. acquired MicroVention Inc., a company that treats diseases in small blood vessels of the brain. Both companies have experienced tremendous success and growth as a result of this synergistic merger.
“Terumo has provided the resources to allow us to invest and grow our business, as well as the opportunity to innovate products for Terumo,” MicroVention CEO Richard Cappetta said.
To further complement its growth plans, Terumo acquired Sequent Medical, Inc., a privately held firm in California that was absorbed into MicroVention. The new venture will allow MicroVention to expand its product portfolio in aneurysm therapy by utilizing the new technologies gained from the acquisition.
“Sequent has a proprietary braiding technology and developed the WEB Aneurysm Embolization System, a mesh created from extremely fine wire for the treatment of both ruptured and unruptured aneurysms,” Cappetta explained.
Following its recent integration with Sequent, MicroVention now has a stronger product portfolio that will establish its leading position in neurovascular disorders. Already launched in Europe, WEB is a therapy that may provide increased patient safety and improved clinical outcomes. With the shorter procedure, patients should face less risk of complications.
Valuing the independence provided by its parent company, MicroVention continues to innovate in patient care and remains prolific in product development.
Since its establishment 20 years ago, the company has expanded to cover a comprehensive portfolio of neurovascular disorders that include aneurysm, stroke and carotid artery disease and neurovascular malformation treatment solutions. Over the same period, the company has seen its revenue increase tenfold and its workforce grow from 130 employees to nearly 2,000 scattered across the globe.
“We are proud of what we do here to save lives because our innovative products help with many diseases. You are going to see from us very strong growth over the next 10 years with a robust pipeline of products,” said Cappetta.